Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Novel Therapeutic Approaches for Pulmonary Arterial Hypertension"
A special issue of Journal of Clinical Medicine (ISSN 2077-0383).
Deadline for manuscript submissions: closed (31 January 2017).
Pulmonary arterial hypertension (PAH) is a life-threatening cardiopulmonary disease that is characterized by hypertrophic vascular remodeling of small distal pulmonary arteries with near obliteration of the vessel lumen, increased pulmonary vascular resistance, and pulmonary artery hypertensive pressures. These adverse hemodynamic parameters affect right ventricular-pulmonary artery coupling and ultimately lead to right ventricular failure and premature death. Advances have been made in contemporary pharmacotherapies with combination drugs, including agents that target the nitric oxide, prostacyclin, and endothelin signaling pathways. Despite this, patients continue to have progression of disease with adverse clinical events and outcomes. This has led to the search for novel and innovative therapeutic interventions to target the pulmonary vasculature, the right ventricle or both. Studies to identify novel disease mediators have become a priority and include next generation genetic sequencing, metabolomic profiling, and proteomic analyses. Other advances in the field involve utilizing data from these studies for gene therapies that can be delivered using aerosol, intravenous, or intracoronary delivery approaches. Cell therapy has been another area of active interest, especially with respect to treating the right ventricle. Other therapy in the early days of investigation is pulmonary artery denervation, which denervates the large pulmonary arteries to decrease sympathetic tone and, thereby, promote vasorelaxation. Together these and other novel therapies will advance the field and modify the pulmonary vascular and right ventricular disease pathophenotype to improve clinical outcomes.
Assoc. Prof. Jane A. Leopold
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Pulmonary arterial hypertension
- Right ventricular dysfunction
- Whole genome sequencing/whole exome sequencing
- Metabolomic profiling and metabolic modulators
- Proteomic analysis
- Gene therapy
- Cell therapy
- Chemotherapeutic agents
- Pulmonary artery denervation